Objectives: Src family kinases (SFKs) are expressed in non-small cell lung cancer (NSCLC) and may be involved in tumor growth and metastases. Inhibition of SFK may also enhance radiation. The purpose of this study was to evaluate if a maximum dose of 100 mg of dasatinib could be safely administered with concurrent chemoradiation and then continued as maintenance for patients with newly diagnosed stage III NSCLC. Methods: Patients with stage III locally advanced NSCLC received paclitaxel, 50 mg/m2/week, with carboplatin area under the curve (AUC) = 2, weekly for 7 weeks, and concurrent radiotherapy, 64.8 Gy. Three dose levels of dasatinib 50, 70, and 100 mg/day were planned. Results: 11 patients with locally advanced NSCLC were entered. At the 70 mg dose level 1 patient had grade 5 pneumonitis not responsive to therapy, and one patient had reversible grade 3 pneumonitis and grade 3 pericardial effusion. Due to these toxicities the Brown University Oncology Group Data Safety Monitoring Board terminated the study. Conclusion: Dasatinib could not be safely combined with concurrent chemoradiation for stage 3 lung cancer due to pneumonitis. © 2012 Khurshid, Dipetrillo, Ng, Mantripragada, Birnbaum, Berz, Radie-Keane, Perez, Constantinou, Luppe, Schumacher, Leonard and Safran.
CITATION STYLE
Khurshid, H., Dipetrillo, T., Ng, T., Mantripragada, K., Birnbaum, A., Berz, D., … Safran, H. (2012). A phase I study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer. Frontiers in Oncology, 2 MAY. https://doi.org/10.3389/fonc.2012.00056
Mendeley helps you to discover research relevant for your work.